Attention Medical Professionals! Changes in the Instruction for the use of the medicinal product Meropenem powder for preparation of intravenous solution, manufactured by PJSC "Kraspharma", registration number LP-000189. In accordance with the requirement
09.05.2015
Attention Medical Professionals! Changes in the Instruction for the use of the medicinal product Meropenem powder for preparation of intravenous solution, manufactured by PJSC "Kraspharma", registration number LP-000189. In accordance with the requirement
In accordance with the requirements outlined in the letter from the Federal State Budgetary Institution "National Center for Expertise and Evaluation of Medicines" of the Ministry of Health of Russia dated 09.09.2014 No. 10804, and based on current clinical experience with the medicinal product Meropenem in powder form for preparation of intravenous solution, with doses of 0.5 g and 1 g, manufactured by PJSC "Kraspharma", registration number LP-000189, the Instruction for use has been updated. The changes include the following sections:
The updated Instruction for use, containing this information, was approved by the Ministry of Health of Russia on August 18, 2015.
According to the Instruction for use effective from August 18, 2015, the medicinal product Meropenem in powder form for preparation of intravenous solution in doses of 0.5 g and 1 g, manufactured by PJSC "Kraspharma", registration number LP-000189, is pharmaceutically equivalent to the original meropenem. It can be used for the same indications, at the same doses, for the same duration of the course, and has a similar spectrum of adverse reactions and drug interactions as the original meropenem.
- Pharmacodynamics
- Indications for use
- Contraindications
- Use with caution
- Method of administration and dosage
- Side effects
- Drug interactions
- Special instructions
The updated Instruction for use, containing this information, was approved by the Ministry of Health of Russia on August 18, 2015.
According to the Instruction for use effective from August 18, 2015, the medicinal product Meropenem in powder form for preparation of intravenous solution in doses of 0.5 g and 1 g, manufactured by PJSC "Kraspharma", registration number LP-000189, is pharmaceutically equivalent to the original meropenem. It can be used for the same indications, at the same doses, for the same duration of the course, and has a similar spectrum of adverse reactions and drug interactions as the original meropenem.
